All of the following criteria must be met in order to be enrolled in the study:
Age ≥18 years
Life expectancy ≥6 months
Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade \<=1)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Breast cancer only:
* Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)
* Planned minimum of 6 cycles of chemotherapy
Lymphoma only:
* Incident lymphoma initiating treatment with vincristine
* Planned minimum of 4 cycles of chemotherapy
Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment
Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)
Written informed consent given
Enrollment must be completed prior to receiving the first dose of chemotherapy
You may not be if
Evidence of central nervous system metastases
Evidence of clinically significant peripheral neuropathy (CTCAE \>2) as defined by patient report of frequent numbness or tingling in the hands or feet
Any uncontrolled serious illness or medical condition that would impact the conduct of the current study
Previous exposure to neurotoxic chemotherapy drugs
Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury
General anesthesia less than one month prior to the first dose of neurotoxic chemotherapy
Clareo Health | Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
